Transaction in Own Shares

Summary by AI BETAClose X

Templeton Emerging Markets Investment Trust PLC announced a transaction in its own shares, purchasing 423,000 Ordinary shares for cancellation at a price of 254.38 pence per share on 16 January 2026. Following this buyback, the Company's issued share capital stands at 956,609,249 Shares, with 60,000,000 Shares held in Treasury, resulting in a total of 956,609,249 voting rights. Shares held in treasury will only be reissued above the prevailing Net Asset Value per share to protect existing shareholders. This new total number of voting rights should be used by shareholders for FCA Disclosure Guidance and Transparency Rules notification calculations.

Disclaimer*

Templeton Emerging Markets IT PLC
16 January 2026
 

Stock Exchange Announcement

Templeton Emerging Markets Investment Trust PLC ("the Company")

Transaction in Own Shares

Legal Entity Identifier 5493002NMTB70RZBXO96

 

 

The Company announces that, on 16 January 2026, it purchased for cancellation 423,000 Ordinary shares of 5 pence each in the Company ("Shares") at a price of 254.38 pence per Share.

 

Following this transaction, the Company's share capital consists of 956,609,249 Shares in issue and 60,000,000 Shares held in Treasury. Therefore, the total number of voting rights in the Company is 956,609,249. In order to protect the interests of existing shareholders, shares held in treasury will only be reissued at a price above the prevailing NAV per share at the time of reissue.

 

This figure (956,609,249) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information please e-mail temitcosec@franklintempleton.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings